Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30848028 | 1.00 | SCN9A (0.34) | SCN9ACYP2C9CYP2C19RXRAGRIN1 | |
| SCHEMBL27132348 | 0.91 | SLC40A1 (0.38) | SCN9ARXRAGRIN1GRIN2B | |
| SCHEMBL30847993 | 0.91 | SLC40A1 (0.38) | SCN9ARXRAGRIN1GRIN2B | |
| SCHEMBL30847861 | 0.89 | RXRA (0.37) | SCN9ARXRAGRIN1GRIN2B | |
| SCHEMBL27132406 | 0.89 | RXRA (0.37) | SCN9ARXRAGRIN1GRIN2B | |
| SCHEMBL30848042 | 0.88 | RXRA (0.36) | SCN9ARXRAGRIN1GRIN2BKCNT1 | |
| SCHEMBL27132783 | 0.88 | RXRA (0.36) | SCN9ARXRAGRIN1GRIN2BKCNT1 | |
| SCHEMBL30848066 | 0.87 | RXRA (0.34) | SCN9ARXRAGRIN1GRIN2BLRRK2 | |
| SCHEMBL27132716 | 0.87 | RXRA (0.34) | SCN9ARXRAGRIN1GRIN2BLRRK2 | |
| SCHEMBL30848041 | 0.84 | RXRA (0.38) | SCN9ARXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | SCN9A 1573/4885CYP2C9 3468/4885CYP2C19 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.